CardieX Future Growth

Future criteria checks 5/6

CardieX is forecast to grow earnings and revenue by 136.7% and 72.7% per annum respectively. EPS is expected to grow by 150.1% per annum. Return on equity is forecast to be 4% in 3 years.

Key information

136.7%

Earnings growth rate

150.1%

EPS growth rate

Medical Equipment earnings growth	16.4%
Revenue growth rate	72.7%
Future return on equity	4.0%
Analyst coverage	Low
Last updated	06 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

ASX:CDX - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	52	24	24	24	1
6/30/2025	18	-3	-3	-3	1
6/30/2024	12	-8	-8	-8	N/A
3/31/2024	13	-9	-7	-7	N/A
12/31/2023	14	-9	-5	-5	N/A
9/30/2023	10	-14	-9	-9	N/A
6/30/2023	6	-19	-12	-12	N/A
3/31/2023	5	-16	-11	-11	N/A
12/31/2022	4	-14	-10	-10	N/A
9/30/2022	4	-13	-10	-9	N/A
6/30/2022	5	-12	-10	-9	N/A
3/31/2022	5	-11	-9	-8	N/A
12/31/2021	5	-10	-8	-8	N/A
9/30/2021	5	-7	-6	-6	N/A
6/30/2021	6	-5	-4	-4	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	5	-3	-2	-2	N/A
9/30/2020	5	-3	-2	-2	N/A
6/30/2020	5	-3	-2	-2	N/A
3/31/2020	5	-3	-2	-2	N/A
12/31/2019	5	-4	-2	-2	N/A
9/30/2019	5	-3	-2	-2	N/A
6/30/2019	5	-3	-3	-2	N/A
3/31/2019	5	-3	-3	-3	N/A
12/31/2018	4	-3	-3	-3	N/A
9/30/2018	4	-3	-2	-2	N/A
6/30/2018	4	-3	-2	-2	N/A
3/31/2018	5	-3	N/A	-2	N/A
12/31/2017	5	-4	N/A	-2	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	5	-4	N/A	-3	N/A
3/31/2017	5	-4	N/A	-4	N/A
12/31/2016	5	-4	N/A	-4	N/A
9/30/2016	5	-5	N/A	-5	N/A
6/30/2016	5	-5	N/A	-5	N/A
3/31/2016	5	-4	N/A	-4	N/A
12/31/2015	4	-4	N/A	-4	N/A
9/30/2015	5	-3	N/A	-3	N/A
6/30/2015	5	-1	N/A	-2	N/A
3/31/2015	5	-2	N/A	-2	N/A
12/31/2014	5	-2	N/A	-3	N/A
9/30/2014	5	-2	N/A	-2	N/A
6/30/2014	5	-3	N/A	-1	N/A
3/31/2014	6	-2	N/A	0	N/A
12/31/2013	6	0	N/A	1	N/A
9/30/2013	8	1	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: CDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDX is expected to become profitable in the next 3 years.

Revenue vs Market: CDX's revenue (72.7% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: CDX's revenue (72.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CDX's Return on Equity is forecast to be low in 3 years time (4%).

CardieX Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies